000			01481 a2200445 4500
005			20250516172912.0
264		0	_c20140114
008			201401s 0 0 ger d
022			_a1661-8157
024	7		_a10.1024/1661-8157/a001431 _2doi
040			_aNLM _beng _cNLM
100	1		_aCurkovic, Ivanka
245	0	0	_a[Thrombocyte aggregation inhibitors: what are the risks?]. _h[electronic resource]
260			_bPraxis _cOct 2013
300			_a1243-50 p. _bdigital
500			_aPublication Type: Journal Article; Review
650	0	4	_aAdenosine _xadverse effects
650	0	4	_aAngioplasty, Balloon, Coronary
650	0	4	_aAspirin _xadverse effects
650	0	4	_aClopidogrel
650	0	4	_aCoronary Disease _xblood
650	0	4	_aDrug Interactions
650	0	4	_aDrug Resistance
650	0	4	_aDrug Therapy, Combination
650	0	4	_aHemorrhage _xblood
650	0	4	_aHumans
650	0	4	_aPiperazines _xadverse effects
650	0	4	_aPlatelet Aggregation Inhibitors _xadverse effects
650	0	4	_aPrasugrel Hydrochloride
650	0	4	_aRandomized Controlled Trials as Topic
650	0	4	_aRisk Factors
650	0	4	_aStents
650	0	4	_aThiophenes _xadverse effects
650	0	4	_aTicagrelor
650	0	4	_aTiclopidine _xadverse effects
700	1		_aEgbring, Marco
700	1		_aKullak-Ublick, Gerd A
773	0		_tPraxis _gvol. 102 _gno. 20 _gp. 1243-50
856	4	0	_uhttps://doi.org/10.1024/1661-8157/a001431 _zAvailable from publisher's website
999			_c23136502 _d23136502